- Troriluzole, an oral, once-daily tablet that modulates glutamate, is being studied as a symptomatic treatment for mild-to-moderate Alzheimer's disease in the T2 Protect AD Study
- The independent Data Safety Monitoring Board (DSMB) completed its review of the prespecified interim futility analysis and communicated that futility was not met
- In order to pass the interim futility analysis, troriluzole had to demonstrate numerically greater benefit over placebo on at least one of the two pre-specified criteria at 26 weeks: (i) cognitive function as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) or (ii) hippocampal volume as assessed by magnetic resonance imaging
PR Newswire
NEW HAVEN, Conn., Dec. 6, 2019